Randomized clinical trial of folate supplementation in patients with peripheral arterial disease

British Journal of Surgery

Volumn 96, Issue 9, 2009, Pages 990-998

  Khandanpour, N ^a,b   Armon, M P ^a   Jennings, B ^b   Finglas, P M ^c   Willis, G ^a   Clark, A ^b   Meyer, F J ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c INSTITUTE OF FOOD RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HOMOCYSTEINE; PLACEBO;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLIC ACID BLOOD LEVEL; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; BLOOD FLOW VELOCITY; CARDIOVASCULAR AGENTS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; TETRAHYDROFOLATES; TREATMENT OUTCOME;

EID: 69249128357     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6670     Document Type: Conference Paper

References (34)

1. Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med 2000; 160: 2934-2938.
2. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-392.
3. Völler H. Peripheral arterial disease (PAD): secondary prevention. Dtsch Med Wochenschr 2002; 127: 1870-1872.
4. HESonline. Inpatient Data: 2005-06 Financial Year, Hospital Episode Statistics (HES). http://www.hesonline.nhs.uk/Ease/servlet/ContentServer? siteID=1937&categoryID=192 [accessed 8 July 2009].
5. Mölgaard J, Malinow MR, Lassvik C, Holm AC, Upson B, Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med 1992; 231: 273-279.
6. van den Berg M, Stehouwer CD, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996; 16: 165-171.
7. Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB, Ascherio A. The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. J Nutr 2003; 133: 2863-2867.
8. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999; 34: 2002-2006.
9. Kelly P, McPartlin J, Goggins M, Weir DG, Scott JM. Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr 1997; 65: 1790-1795.
10. Pietrzik K, Bohlmann A, Fohr I, Prinz-Langenohl R. 5- Methyltetrahydrofolate (MTHF) versus pteroylmonoglutamic acid (PGA) - what is the better alternative for supplementation? FASEB J 2001; 15: 491.4.
11. Troen AM, Mitchell B, Sorensen B, Wener MH, Johnston A, Wood B et al. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr 2006; 136: 189-194.
12. Eprova AG. About Metafolin®. http://www.metafolin.com/servlet/PB/ menu/1784410/index.html [accessed 8 July 2009].
13. Prinz-Langenohl R, Fohr I, Tobolski O, Finglas P, Pietrzik K. Bioavailability of 6S-5-methyltetrahydrofolate relative to folic acid. Bioavailability, Interlaken, 2001.
14. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-364.
15. O'Broin S, Kelleher B. Microbiological assay on microtitre plates of folate in serum and red cells. J Clin Pathol 1992; 45: 344-347.
16. British National Institute of Food Research. Folate. http://www.ifr.ac.uk/folate/ [accessed 8 July 2009].
17. Carrero JJ, López-Huertas E, Salmerón LM, Baró L, Ros E. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr 2005; 135: 1393-1399.
18. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593-1600.
19. Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. Am J Hypertens 2000; 13: 105-110.
20. Williams C, Kingwell BA, Burke K, McPherson J, Dart AM. Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype. Am J Clin Nutr 2005; 82: 26-31.
21. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369: 1876-1882.
22. Tso TK, Huang HY, Chang CK, Huang WN. A positive correlation between homocysteine and brachial-ankle pulse wave velocity in patients with systemic lupus erythematosus. Clin Rheumatol 2006; 25: 285-290.
23. Im JA, Lee JW, Shim JY, Lee HR, Lee DC. Association between brachial-ankle pulse wave velocity and cardiovascular risk factors in healthy adolescents. J Pediatr 2007; 150: 247-251.
24. McNulty H, Pentieva K, Hoey L, Ward M. Homocysteine, B-vitamins and CVD. Proc Nutr Soc 2008; 67: 232-237.
25. Ashfield-Watt PA, Pullin CH, Whiting JM, Clark ZE, Moat SJ, Newcombe RG et al. Methylenetetrahydrofolate reductase 677C → T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. Am J Clin Nutr 2002; 76: 180-186.
26. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996; 275: 1893-1896.
27. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003; 290: 932-940.
28. Schernthaner GH, Plank C, Minar E, Bieglmayer C, Koppensteiner R, Schernthaner G. No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease. Eur J Clin Invest 2006; 36: 333-339.
29. Solini A, Santini E, Ferrannini E. Effect of short-term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects. Int J Obes (Lond) 2006; 30: 1197-1202.
30. Fisher M, Cushman M, Knappertz V, Howard G. An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration. Am Heart J 2008; 156: 106-111.
31. Venn BJ, Green TJ, Moser R, Mann JI. Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study. Am J Clin Nutr 2003; 77: 658-662.
32. Houghton LA, Sherwood KL, Pawlosky R, Ito S, O'Connor DL. [6S]-5-Methyltetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation. Am J Clin Nutr 2006; 83: 842-850.
33. Gelosa P, Cimino M, Pignieri A, Tremoli E, Guerrini U, Sironi L. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag 2007; 3: 567-577.
34. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97: 716-720.